Effect of Statin Therapy on C-Reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00655993|
Recruitment Status : Unknown
Verified April 2008 by VA Loma Linda Health Care System.
Recruitment status was: Recruiting
First Posted : April 10, 2008
Last Update Posted : April 10, 2008
|Condition or disease||Intervention/treatment||Phase|
|COPD Inflammation||Drug: simvastatin||Phase 1|
Patients with chronic obstructive lung disease (COPD) have an ongoing systemic inflammation, which can be assessed by measuring C-reactive protein (CRP). CRP is found to be a strong and independent predictor of future COPD outcomes. Statins are a class of cholesterol lowering drugs that decrease mortality from cardiovascular disease and stroke. In addition, they have anti-inflammatory, anti-thrombotic and immunomodulatory properties. Statins lower C-reactive protein by the ability to reduce the production of interleukin (IL)-6, the cytokine that activates the acute phase CRP response.
Thus the rationale for this study is to evaluate effect of statins on the levels of CRP and ET-1 in COPD patients.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effect of Statin Therapy on C-Reactive Protein Levels in Patients With COPD|
|Study Start Date :||April 2008|
|Estimated Primary Completion Date :||March 2009|
|Estimated Study Completion Date :||December 2009|
Placebo Comparator: 1
40 mg po daily
Active Comparator: 2
40 mg po daily
- serum CRP levels [ Time Frame: 9 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00655993
|Contact: Hemal J. Parekh, M.D.||909-825-7084 ext email@example.com|
|Contact: Lennard Specht, M.D.||909-825-7084 ext firstname.lastname@example.org|
|Principal Investigator:||Lennard Specht, M.D.||VA Loma Linda Health Care System|
|Principal Investigator:||Hemal J. Parekh, M.D.||VA Loma LInda Healthcare System|
|Principal Investigator:||James D. Anholm, M.D.||VA Loma Linda Healthcare System|